Project Grant R01CA292407
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$484K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This $439,644 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports fundamental scientific investigations into the molecular and cellular mechanisms underlying acute myeloid leukemia (AML). The primary objectives are to: 1) investigate the relationship between specific mutations and leukemia stem cell frequency, disease initiation, and disease maintenance; 2) evaluate in vivo dynamics of individual AML stem cells using single-cell...
The National Cancer Institute (NCI) awarded a $458,698 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Regents of the University of Michigan. The grant, titled "Genes Regulating Stem and Progenitor Cell Expansion and Relapse in Acute Myeloid Leukemia", aims to study novel genes that influence normal and leukemic stem/progenitor cell expansion, and their contributions to therapy resistance and relapse in acute myeloid leukemia (AML). The 5-year project...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports the development of novel inhibitors and proteolysis targeting chimeras (PROTACs) that target the ENL protein, a key driver of acute myeloid leukemia (AML) with mixed-lineage leukemia (MLL) gene rearrangements. The $476,558 award to Texas A&M University aims to: 1) develop more potent, stable, and selective small molecule ENL inhibitors and PROTACs; 2)...
This $698,008 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research conducted by The Trustees of the University of Pennsylvania to investigate the relationship between branched-chain amino acid metabolism and histone propionylation, a chromatin modification associated with gene expression, in pancreatic ductal adenocarcinoma (PDA). The project aims to elucidate the mechanisms by which nuclear-localized branched-chain...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has awarded a $502,516 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Case Western Reserve University's Office of Research Administration. This 5-year grant, starting on April 1, 2025, aims to further investigate the impacts of newly developed small molecule degraders that target the nuclear-specific Heat Shock Transcription Factor 1 (HSF1) on leukemic stem cell self-renewal in...
This federal Project Grant award of $614,749.00 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at the University of Texas Health Science Center at San Antonio (UTHSCSA) to investigate the therapeutic potential and mechanistic actions of the PSPC1 protein in acute myeloid leukemia (AML).
The key objectives of the research are to: 1) elucidate the developmental and functional roles of PSPC1 in AML pathogenesis through genetically engineered...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides funding to The Leland Stanford Junior University (Stanford University) to investigate key questions related to pre-leukemic hematopoietic stem cell (PHSC) clonal evolution, kinetics, and cell non-autonomous effects. The goal is to understand how features of the pre-leukemic phase and the PHSCs themselves contribute to the pathogenesis of acute myeloid leukemia (AML). The...
This federal Project Grant award, funded by the National Cancer Institute's Cancer Biology Research program (CFDA 93.396), supports fundamental research into the role of long noncoding RNAs in acute myeloid leukemia (AML). The $415,259 award, which runs from August 1, 2024 to July 31, 2026, will be performed by the Rector & Visitors of the University of Virginia.
The key objectives of the project are to: 1) Determine the role of a specific regulatory RNA in primary and relapsed AML, and...
This National Cancer Institute (NCI) Project Grant award under the Cancer Biology Research program (CFDA 93.396) provides $444,952 in funding to the University of California, San Diego (UCSD) to explore the impact of base deaminase deregulation on the evolution of precancerous cells to acute myeloid leukemia.
The primary objective is to elucidate the relative roles of the APOBEC3C and ADAR1 base deaminases in driving the transformation of pre-leukemic stem cells (pre-LSCs) to leukemic stem...
This $878,400 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Biology Research program (CFDA 93.396) will fund research characterizing vitamin B6 pathway dependency in acute myeloid leukemia (AML) at Cold Spring Harbor Laboratory from January 2023 through December 2027. The research aims to further the understanding of the underlying mechanisms of AML by studying abnormal vitamin pathways and metabolic programming...